《阿斯利康AstraZeneca（AZN）：2022年企业治理报告「LSE」（英文版）（228页）.pdf》由会员分享，可在线阅读，更多相关《阿斯利康AstraZeneca（AZN）：2022年企业治理报告「LSE」（英文版）（228页）.pdf（228页珍藏版）》请在三个皮匠报告上搜索。

1、What science can doAstraZeneca Annual Report and Form 20-F Information 2022Science can.Front cover and inside front cover images:Unlocking the potential of the complement system.The dysregulation of the complement system,an essential part of the immune system,is a key driver of many devastating dise

2、ases.Targeting and inhibiting the complement system before it can trigger tissue damage or destruction can help restore balance.We are committed to continue unlocking the potential of the complement system,to discover new life-changing therapies for even more patients.Use of terms:In this Annual Rep

3、ort,unless the context otherwise requires,AstraZeneca,the Group,we,us and our refer to AstraZeneca PLC and its consolidated entities.We are a global,science-led,patient-focused pharmaceutical company.From the beginning,science has been at the front and centre of everything we do,taking us to places

4、we never thought possible.This is the adventure of what science can do See what science can do on page 00Key For more information within this Annual Report For more information,see BV Denotes sustainability information independently assured by Bureau VeritasOur SupplementsDetailed information on our

5、 Development Pipeline,Patent Expiries and Key Marketed Products and Risk.See our website, Science can.We are a global,science-led,patient-focused pharmaceutical company.We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people,society and the

6、planet.See what science can do on page 2Our SupplementsDetailed information on our Development Pipeline,Patent Expiries and Key Marketed Products and Risk.See our website, For more information within this Annual Report.For more information,see .BV Denotes sustainability information independently ass